Slide 1: Investor Presentation
Investor Presentation May 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM
Slide 2: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Agenda
Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Growth Segments • Small Molecules • Biosimilars • Branded Formulations • Novel Molecules • Research Services - Syngene Five Year Financial Highlights Outlook 3
Slide 4: Biocon: Who are we?
Biocon: Who are we? 4
Slide 5: Biocon: Asia's Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe 5
Slide 6: The Biocon Journey: A continuous evolution
The Biocon Journey: A continuous evolution Successful IPO, Biocon listed in India Poised for global impact Building the India Business with Biosimilar insulins An Enzymes Company and expertise in biologics & Antibodies People: 250 Revenue: ₹ 11,940 Million Target US$1bn in sales Revenue: ₹ 320 Milli
Slide 7: Evolution of Key Innovations: Making a Difference
Evolution of Key Innovations: Making a Difference 1979 - First Indian company to manufacture and export enzymes to US and Europe 2001 - First Indian company to be approved by US FDA for the manufacture of lovastatin from solid state fermentation 2004 - First company worldwide to commercialize generi
Slide 8: FY16 - Business Highlights
FY16 - Business Highlights Biocon's Insulin Glargine received regulatory approval in Japan Biocon successfully listed Syngene, its Biocon’s Research Services subsidiary after a highly successful IPO Four lead biosimilars programs progressed further through the clinic. US/EU biosimilar filings planne
Slide 9: Financial Highlights – Q4 & FY16
Financial Highlights – Q4 & FY16 All Figures in ₹ Million except % Particulars Q4 FY16 Q4 FY15 Growth FY16 FY15 Growth Revenue 10,035 8,545 17% 35,699 31,429 14% EBITDA 2,378 2,020 18% 9,045 7,489 21% Net Profit* 3,609 2,015 79% 8,961 4,974 80% R&D Expenses in P&L 998 560 78% 2,750 1,688 63% Gross R
Slide 10: Business Segments
Business Segments 10
Slide 11: Growth Verticals: Aligned with Shifting Paradigms
Growth Verticals: Aligned with Shifting Paradigms 1. (a) APIs and (b) Generic Formulations Small Molecules 5. Contract Research & Manufacturing 2. Exports of Insulins, MAbs & Research Biosimilars Other Biologics Services (Biologics & (Syngene) g. Insulins) Growth Verticals Novel Branded Molecules Fo
Slide 12: 1a. Small Molecule APIs
1a. Small Molecule APIs Product Portfolio which leverages our core fermentation capabilities and have a high degree of complexity. Early mover in niche products at commercial scale. One of the largest producers of various fermentation based statins and immunosuppressant API in India and across the g
Slide 13: 1b. Small Molecule Generic Formulations
1b. Small Molecule Generic Formulations Nascent pipeline To file ~20-25 dossiers in the next few years Pipeline includes solid oral & parenteral products in both potent & non-potent categories of compounds. Product pipeline comprises of ‘difficult to make,’ technology intensive molecules for emergin
Slide 14: 2. Biosimilars
2. Biosimilars Amongst the largest portfolio of Biosimilars globally straddling human insulin/insulin analogs, monoclonal antibodies and other biologics. Addressable market size: ~US$60 Billion Strong scientific and technical capabilities and manufacturing expertise to address global opportunities.
Slide 15: Biosimilars: Growth through partnership
Biosimilars: Growth through partnership BIOCON MYLAN • Global-scale, complex biologics manufacturing capabilities • Strength in Regulatory/ filings strategy • Facilities accredited by international regulatory agencies • Strong commercialization capability in US and EU. • Decade-long experience & dem
Slide 16: Global Biosimilars Pipeline – US$60 bn opportunity
Global Biosimilars Pipeline – US$60 bn opportunity Market Size* Molecule Type Status (US$ bn) Rh Insulin Recombinant Human Insulin EU Phase 3 complete 3.1 INSULINS Glargine Long Acting Basal Insulin Global Phase 3 7.1 Aspart Rapid Acting Insulin Analog Preclinical/Scale Up 4.7 Lispro Rapid Acting In
Slide 17: Biosimilar Pipeline: Biocon well placed in the competitive landscape
Biosimilar Pipeline: Biocon well placed in the competitive landscape 2015 Molecule Sales* Biosimilar Development Pipeline@ (US$ bn) Pre-Clinical Phase I Phase III/Filed pegfilgrastim 4.7 Pfizer Dr. Reddy’s Biocon, Sandoz, Apotex, Coherus, Richter trastuzumab 6.8 Oncobiologics, Dr. Reddy's Hanhwa, Ge
Slide 18: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Biocon Malaysia: Asia’s largest integrated insulins manufacturing facility Biocon’s First Manufacturing expansion overseas in Iskandar, Johor. Capital Investment of over US$200mn in the first phase. Emerging market filings planned for FY17. Disposable
Slide 19: 3. Branded Formulations
3. Branded Formulations • An India focused Specialty Business with Regional Ambitions • Strategy focused around biologics and differentiated products as anchor brands. • Organized into 6 key divisions around chronic therapy areas • Metabolics Division - Combination of brands in diabetes and cardiova
Slide 20: 4. Novel Molecules: Lead Programs
4. Novel Molecules Insulin Tregopil • Multiple sets of studies completed to establish Post Prandial glycemic control First-in-Class Oral • Phase 2 ready, global studies planned Prandial Insulin • Sizeable global opportunity In – house program Itolizumab • Commercialized in India for Psoriasis. • LEA
Slide 21: 5. Syngene (Research Services Business)
5. Syngene (Research Services Business) Global High Growth CRO Company Attractive Blue Chip Customer Base • One of the leading India-based contract research • Highly successful track-record in molecule organizations (CRO) development • Integrated discovery and development • Client base includes 8 of
Slide 22: Five Year Financials & Outlook
Five Year Financials & Outlook 22
Slide 23: Financial Performance Summary (FY12-16)
Financial Performance Summary (FY12-16) All Figures in ₹ Million except EPS Business Segment FY12 FY13 FY14 FY15 FY16 Biopharmaceuticals 16,764 18,705 21,382 22,367 23,908 - Biopharma 14,170 15,231 17,468 18,071 19,534 - Branded Formulations 2,594 3,474 3,914 4,296 4,374 Contract Research 4,101 5,57
Slide 24: Aspiring for $1 Billion in Revenues by FY19
Aspiring for $1 Billion in Revenues by FY 19 Key Focus Areas o Small Molecules & Generic Formulations- Improved product mix incl. ANDAs 25% o Biosimilars - Meaningful near term growth to be driven 30% by emerging markets, ramp up post developed market entry o Branded Formulations –Strategy focused a
Slide 25: Appendix
Appendix 25
Slide 26: Business Holdings Structure
Business Holdings Structure BIOPHARMA SUBSIDIARIES Biocon Research, India | 100% R&D- Novel Molecules & Biosimilars Biocon Pharma, India | 100% Manufacturing - Generic Formulations Biocon Pharma Inc., USA | 100% Step Down Subsidiary ~61% | Promoters Biocon Sdn. Bhd, Malaysia | 100% ~ 2% | Employees
Slide 27: For more information, please visit www.biocon.com
For more information, please visit www.biocon.com Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: saurabh.paliwal@biocon.com 27